Jørgensen will stay on as CEO temporarily for an undetermined period of time “to support a smooth transition” as the company looks for his replacement. Novo Nordisk’s value more than ...

"Although it might satisfy some for investors to drive a CEO transition, without meaningful change in near-term strategy, we continue to see a more difficult path forward," he said. Novo Nordisk ...

As part of the transition period, Lars Rebien Sørensen ... with operating profit ranging from approximately $5.4 to $6.3 billion. 2 “Serving as Novo Nordisk’s CEO for the past eight years has been a ...

In connection with the leadership transition, Lars Rebien Sørensen, Chair of the Novo Nordisk Foundation and former CEO of NVO, will initially join the company’s board as an observer, to be nominated ...